Ligand id: 7877

Name: infigratinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 95.09
Molecular weight 559.19
XLogP 3.49
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Various Phase II clinical trials assessing BGJ-398 are underway, including NCT02160041 for solid tumors and hematologic malignancies and NCT02257541 (in combination with imatinib mesylate for untreated advanced gastrointestinal stromal tumor (GIST)). Click here to link to's complete listing of BGJ-398 trials.
Mechanism Of Action and Pharmacodynamic Effects
FGFRs are a family of receptor tyrosine kinases which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival. Inhibition of these receptors may result in the inhibition of tumor angiogenesis and proliferation, and the induction of tumor cell death.